Estimated Time to Complete Activity: 60 minutes


Statement of Need
Survival rates of patients with lung cancer have not significantly improved in the past 5 years, and lung cancer remains the leading cause of cancer-related death in the United States, despite the introduction of several novel anticancer therapies. Clinical trials are key to the development of new treatment regimens that have made an impact in the management of patients with this devastating malignancy. However, only 14% of patients with lung cancer are aware of clinical trials as a treatment option, and fewer than 10% of patients with lung cancer are enrolled in clinical trials. As a result, it has been projected that the current rate of patient enrollment in lung cancer clinical trials is inadequate to sustain the growth of novel therapies. Commitment to collaborate is needed from clinical researchers, patient advocates, government agencies, and private industries to improve clinical trial enrollment and retention through building relationships, strengthening communication, educating patients and caregivers, streamlining protocols, and developing clinical trials that address the most compelling needs in patients with lung cancer. Timely activation, accrual, and completion of clinical trials will ensure that treatment arms in the trial do not lag behind the standard of care and that subsequent results are relevant to current clinical practice. At the end of this activity, participants will be able to explain the importance of clinical trial enrollment and retention in advancing patient care, identify potential barriers that impact enrollment in clinical trials, and discuss strategies that can be used to overcome challenges in recruiting and retaining participants in lung cancer clinical trials.


Purpose
Although it is recognized that clinical trials are critical to the development of new treatment regimens that are needed to improve the treatment of patients with lung cancer, only 14% of patients with lung cancer are aware of clinical trials as a treatment option, and fewer than 10% of patients with lung cancer are enrolled in clinical trials. Commitment from clinical researchers, patient advocates, government agencies, and private industries is needed to improve clinical trial enrollment and retention through building relationships, strengthening communication, educating patients and caregivers, streamlining protocols, and developing clinical trials that address paramount needs in patients with lung cancer. This satellite broadcast will illustrate the importance of clinical trial enrollment and retention in advancing patient care, explain potential barriers that impact enrollment in clinical trials, and discuss strategies that can be used to overcome challenges in recruiting and retaining participants in lung cancer clinical trials.


Target Audience
This activity is intended for clinical researchers, medical oncologists, thoracic surgeons, radiation oncologists, advanced practice nurses, patient advocates, physician assistants, and other healthcare professionals involved in the management of patients with lung cancer.


Educational Objectives
Upon completion of this activity, learners will be able to

1. Discuss the importance of clinical trial enrollment and retention in advancing the treatment of patients with lung cancer.
2. Summarize patient-, physician-, and protocol-related barriers that impact enrollment in lung cancer clinical trials.
3. Evaluate strategies that can be used to overcome challenges in recruiting and retaining patients with lung cancer in clinical trials, especially those who belong to minority or elderly patient subgroups.  

Method of Participation
This activity requires that your computer be configured to access the Internet. A high-speed Internet connection may be required to listen to large files. The podcast will be available on iTunes® and on www.thecbce.com. This activity can also be accessed using an iPhone^®, iPod touch^®, or iPad^® and will be a featured program on the CBCE Oncology CME app for the iPhone, iPod touch, and iPad, which may be downloaded from the Apple^® App Store.


Accreditation
The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.

The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA. 

The CBCE designates this educational activity for 1.0 contact hour.

Accreditation by the American Nurses Credentialing Center’s COA refers to recognition of educational activities and does not imply approval or endorsement of any product.


Webcast Credit Instructions
Successful completion of this activity includes the following:

• Complete the online posttest and score 70% or above.
• Complete the online Evaluation and Request for Credit Form. 

Print your online certificate by selecting the “Print Certificate” button.


CBCE Oncology CME App Credit Instructions With iPhone^®, iPod touch^®, or iPad^®
Successful completion of this activity includes the following:

• Complete the online posttest and score 70% or above.
• Complete the online Evaluation and Request for Credit Form. 

Participants will receive their statement of credit via e-mail 4-6 weeks after submission of the online Evaluation and Request for Credit Form.


Acknowledgement of Commercial Support
The CBCE gratefully acknowledges the educational grant provided by Lilly USA, LLC.


Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.


Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or Lilly USA, LLC. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this activity.


Disclosure of Unlabled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference.

Faculty will inform learners when unlabeled uses will be discussed.


Disclosure of Financial Relationships With Any Commercial Interest
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.


Disclosure of Potential Conflicts of Interest
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.

The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:

Alan Sandler, MD
Advisory Board Member
Abraxis BioScience, LLC
Agennix AG
Allos Therapeutics, Inc.
Boehringer Ingelheim
Biodesix, Inc.
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GlaxoSmithKline
Lilly USA, LLC
NewLink Genetics Corporation
Novartis Pharmaceuticals Corporation
OXiGENE, Inc.
Pfizer Inc.
Roche Diagnostics
Consultant
Abraxis BioScience, LLC
Agennix AG
Allos Therapeutics, Inc.
Boehringer Ingelheim
Biodesix, Inc.
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GlaxoSmithKline
Lilly USA, LLC
NewLink Genetics Corporation
Novartis Pharmaceuticals Corporation
OXiGENE, Inc.
Pfizer Inc.
Roche Diagnostics
Grant/Research Support 
Bristol-Myers Squibb Company
Genentech, Inc.
Lilly USA, LLC
Pfizer Inc.
Honoraria
Agennix AG
Boehringer Ingelheim
Bristol-Myers Squibb Company
Celgene Corporation
Chugai Pharmaceutical Co., Ltd.
Daiichi-Sankyo, Inc.
Genentech, Inc.
GlaxoSmithKline
Lilly USA, LLC
OXiGENE, Inc.
Roche Diagnostics
Quintiles
Legal Consultant
Genentech, Inc.
Pfizer Inc.
OSI Pharmaceuticals, Inc.
Roche Diagnostics
Speaker’s Bureau
Genentech, Inc.
Lilly USA, LLC
Quintiles

Joan Schiller, MD
Advisory Board
Agennix AG
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals
Biodesix, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Daiichi-Sankyo, Inc.
Genentech, Inc.
Lilly USA, LLC
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Oncothyreon Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Telik, Inc.
Clinical Studies
Geron Corporation
Synta Pharmaceuticals Corp.
Consultant
Agennix AG
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals
Biodesix, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Daiichi-Sankyo, Inc.
Genentech, Inc.
Lilly USA, LLC
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation
Oncothyreon Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Telik, Inc.

The following faculty declared they have no financial relationships that require disclosure:

Walter J. Curran Jr, MD



Independent Peer Reviewer Disclosure
The peer reviewer had no real or apparent conflicts of interest to report related to this activity.



Institutional Disclosure
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.


Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.